Joel Jiang

8.4k citations

24 papers · 3.6k indexed · 2 hit papers · h-index 16

Impact in

Oncology top 1%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Colorectal Cancer Treatments and Studies
Immunology top 2%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction

Papers in

Oncology 14
- Cancer Immunotherapy and Biomarkers 14
- CAR-T cell therapy research 12
Applied Microbiology and Biotechnology 1

Co-authors: Jedd D. Wolchok James Larkin F. Stephen Hodi Dirk Schadendorf Jeffrey S. Weber Ian M. Waxman Christopher D. Lao Caroline Robert
Journals: Journal of Clinical Oncology (6 papers)JAMA Oncology (2 papers)The Lancet Oncology (2 papers)Annals of the Rheumatic Diseases (1 paper)European Journal of Cancer (1 paper)
Partner nations: United States United Kingdom Spain

In The Last Decade

Joel Jiang

22 papers receiving 3.5k citations

Hit Papers

align trajectories log scale

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial 2018 · 1.0k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2018 The Lancet Oncology
2017 Journal of Clinical Oncology

Peers

Countries citing papers authored by Joel Jiang

Since Specialization

Citations

This map shows the geographic impact of Joel Jiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel Jiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel Jiang more than expected).

Fields of papers citing papers by Joel Jiang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joel Jiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel Jiang. The network helps show where Joel Jiang may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Joel Jiang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Joel Jiang Line = papers co-authored together Joel Jiang links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	POS1072 Icotrokinra, a Targeted Oral Peptide That Selectively Blocks the Interleukin-23-Receptor, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results Through Week 24 of the Phase 3, Randomized, Double-Blind, Placebo-Controlled ICONIC-LEAD Trial Annals of the Rheumatic Diseases ·Robert Bissonnette, Jennifer Soung, Adelaide A. Hebert, Andrew Pink, Andreas Pinter, Yi Shi, 白志义, 敏幸門間, Qiankui Li, Joel Jiang, Cynthia Marie Carver DeKlotz, Mark Lebwohl	2025	0
2	Prognostic indicators of disease progression in Duchenne muscular dystrophy: A literature review and evidence synthesis PLoS ONE ·Chirstopher D. Gascón, Jessica J. Summers, López Aguas, Christian Werner, Joel Jiang, Erik Landfeldt, Katharina Buesch	2022	15
3	Ataluren Delays Loss of Ambulation and Decline in Pulmonary Function in Patients with Nonsense Mutation Duchenne Muscular Dystrophy (2553) Neurology ·Craig M. McDonald, Francesco Muntoni, Mark Rance, Joel Jiang, Allan Kristensen, H Yokota, Francesco Bibbiani, Elizabeth Goodwin, Heather Gordish‐Dressman, Lauren P. Morgenroth, Erik Gahner Larsen, Panayiota Trifillis, M. Tulinius	2021	1
4	Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial The Lancet Oncology ·F. Stephen Hodi, Vanna Chiarion‐Sileni, René González, Jean-Jacques Grob, Piotr Rutkowski, C. Lance Cowey, Christopher D. Lao, Dirk Schadendorf, John Wagstaff, Reinhard Dummer, Pier Francesco Ferrucci, Michael Smylie, Andrew Hill, David Hogg, Iván Márquez‐Rodas, Joel Jiang, Jasmine I. Rizzo, James Larkin, Jedd D. Wolchok Hit paper breakdown →	2018	1009
5	Phase 2a, randomized, double‐blind, placebo‐controlled, multicentre, parallel‐group study of an H₄R‐antagonist (JNJ‐39758979) in adults with uncontrolled asthma Clinical & Experimental Allergy ·Alexa P. Kollmeier, Andrew Greenspan, X. L. Xu, Philip E. Silkoff, Elliot S. Barnathan, Matthew J. Loza, Joel Jiang, Bei Zhou, D. Zhang, Robin L. Thurmond	2018	10
6	Nivolumab in previously treated patients with metastatic squamous NSCLC: Results of a European single-arm, phase 2 trial (CheckMate 171) including patients aged ≥70 years and with poor performance status Annals of Oncology ·Sanjay Popat, Andrea Ardizzoni, T-E. Ciuleanu, Manuel Cobo, К. К. Лактионов, Mária Szilasi, Raffaele Califano, Enric Carcereny, Richard W. Griffiths, Luis Paz‐Ares, Cezary Szczylik, J. Corral, Dolores Isla, Jacek Jassem, W. Appel, Jan P. van Meerbeeck, Jennifer Moriatis Wolf, Joel Jiang, L. Rhoda Molife, E. Felip Font	2017	29
7	Abstract LB-055: Overall survival and safety experience from an expanded access program (EAP) of nivolumab (NIVO) for patients with advanced melanoma (MEL) who progressed after prior ipilimumab (IPI) treatment Cancer Research ·Milton Barros, Haley Merrick, Andréia Cristina de Melo, Sérgio Jobim Azevedo, Bernardo Garicochea, Elaine McWhirter, Michael Smylie, Kasuni Sihombing, Carlos Henrique dos Anjos, Teresa M. Petrella, Matías Chacón, Ming-Lai Lai, Suresh Nair, Alexandre Avila, J Grit, Joel Jiang, Scott Ernst	2017	0
8	Overall survival (OS) analysis from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL). Journal of Clinical Oncology ·David Hogg, Paul B. Chapman, Mario Sznol, Christopher D. Lao, René González, Gregory A. Daniels, Michael Smylie, Ragini R. Kudchadkar, John A. Thompson, William H. Sharfman, Michael B. Atkins, Anna C. Pavlick, Joel Jiang, Alexandre Avila, J Grit, F. Stephen Hodi	2017	6
9	Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma Journal of Clinical Oncology ·Jeffrey S. Weber, F. Stephen Hodi, Jedd D. Wolchok, Suzanne L. Topalian, Dirk Schadendorf, James Larkin, Mario Sznol, Georgina V. Long, Hewei Li, Ian M. Waxman, Joel Jiang, Caroline Robert Hit paper breakdown →	2017	874
10	Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204. Journal of Clinical Oncology ·Hussein Tawbi, Peter Forsyth, Alain P. Algazi, Omid Hamid, F. Stephen Hodi, Stergios J. Moschos, Nikhil I. Khushalani, René González, Christopher D. Lao, Michael A. Postow, Michael B. Atkins, Marc S. Ernstoff, Igor Puzanov, Ragini R. Kudchadkar, Reena Thomas, Ahmad A. Tarhini, Joel Jiang, Alexandre Avila, J Grit, Kim Margolin	2017	97
11	Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial The Lancet Oncology ·Jeffrey S. Weber, U Casslén, Ryan J. Sullivan, Jeffrey A. Sosman, Craig L. Slingluff, Donald P. Lawrence, Theodore F. Logan, Lynn M. Schuchter, Suresh Nair, Leslie A. Fecher, Elizabeth I. Buchbinder, Elmer Berghorn, Mary Ruisi, George Kong, Joel Jiang, Christine E. Horak, F. Stephen Hodi	2016	257
12	Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression JAMA Oncology ·Saby George, Robert J. Motzer, Hans J. Hammers, Bruce G. Redman, Timothy M. Kuzel, Scott S. Tykodi, Elizabeth R. Plimack, Joel Jiang, Ian M. Waxman, Brian I. Rini	2016	142
13	Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). Journal of Clinical Oncology ·Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González, Piotr Rutkowski, Jean‐Jacques Grob, C. Lance Cowey, Christopher D. Lao, Dirk Schadendorf, Pier Francesco Ferrucci, Michael Smylie, Reinhard Dummer, Andrew Hill, John B.A.G. Haanen, Michele Maio, Grant A. McArthur, Damian Walker, Joel Jiang, Christine E. Horak, James Larkin, F. Stephen Hodi	2016	63
14	Efficacy and Safety in Key Patient Subgroups of Nivolumab (Nivo) Alone Or Combined with Ipilimumab (Ipi) Versus Ipi Alone in Treatment-Naive Patients with Advanced Melanoma James Larkin, Pawar Nanabhau Shamrao, A. P. Shvet︠s︡ov, Jean‐Jacques Grob, C. Lance Cowey, Christopher D. Lao, John Wagstaff, David Hogg, A. Bradford Hill, Matteo S. Carlino, Pascal Wolter, Célèste Lebbé, Jacob Schachter, Linzi Thomas, J Hassal, Paul Lorigan, Dorothy G. Walker, Joel Jiang, F. Stephen Hodi, 민종덕	2015	2
15	Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma JAMA Oncology ·James Larkin, Christopher D. Lao, Walter J. Urba, David F. McDermott, Christine E. Horak, Joel Jiang, Jedd D. Wolchok	2015	171
16	3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067) European Journal of Cancer ·James Larkin, Vanna Chiarion‐Sileni, R. Gonzalez, Jean‐Jacques Grob, C. Lance Cowey, Christopher D. Lao, John Wagstaff, David Hogg, Adrian Hill, Matteo S. Carlino, Pascal Wolter, Célèste Lebbé, Jacob Schachter, Linzi Thomas, J.C. Hassel, Paul Lorigan, Damian Walker, Joel Jiang, F. Stephen Hodi, Jedd D. Wolchok	2015	27
17	Effects of JNJ-40929837, a leukotriene A4 hydrolase inhibitor, in a bronchial allergen challenge model of asthma Pulmonary Pharmacology & Therapeutics ·William Barchuk, John M. Lambert, Rainard Fuhr, Joel Jiang, マリノフォーラム, A Fourie, PÂMELA ISADORA SCHUMANN, Philip E. Silkoff, Elliot S. Barnathan, Robin L. Thurmond	2014	18
18	Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease Diabetes Obesity and Metabolism ·J.‐F. Yale, G. Bakris, Bertrand Cariou, Javier Nieto Guevara, Elias David‐Neto, Dennis K. Yue, Ewa Wajs, 川上健志, Joel Jiang, Ga‐Lai Law, Keith Usiskin, Gary Meininger, (unknown)	2014	224
19	Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial American Heart Journal ·Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Kenneth W. Mahaffey, Greg Fulcher, Peter Stein, Mehul Desai, Wayne Shaw, Joel Jiang, Frank Vercruysse, Gary Meininger, David R. Matthews	2013	278
20	Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: A phase III, prospective, multicenter, randomized, double-blind, noninferiority study Clinical Therapeutics ·Christopher Lucasti, Abel Jasovich, Obiamiwe Umeh, Joel Jiang, Koné Kaniga, Ian R. Friedland	2008	79

About Joel Jiang

Joel Jiang is a scholar working on Oncology, Applied Microbiology and Biotechnology, Immunology, Pulmonary and Respiratory Medicine and Endocrinology, Diabetes and Metabolism, having authored 24 papers that have together received 3.6k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (14 papers), CAR-T cell therapy research (12 papers), Melanoma and MAPK Pathways (5 papers), Immunotherapy and Immune Responses (3 papers), Muscle Physiology and Disorders (3 papers), Diabetes Treatment and Management (3 papers), Pancreatic function and diabetes (3 papers) and Respiratory and Cough-Related Research (2 papers). The work is most often cited by research in Oncology (2.4k citations), Immunology (930 citations), Endocrinology, Diabetes and Metabolism (670 citations), Pulmonary and Respiratory Medicine (650 citations) and Genetics (176 citations). Joel Jiang has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include Jedd D. Wolchok, James Larkin, F. Stephen Hodi, Dirk Schadendorf, Jeffrey S. Weber, Ian M. Waxman, Christopher D. Lao, Caroline Robert, Hewei Li and Georgina V. Long. Their work appears in journals such as Journal of Clinical Oncology, JAMA Oncology, The Lancet Oncology, Annals of the Rheumatic Diseases and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact